ABIOMED — Technical Presentation (December 2012)
54 slides from ABIOMED's technical presentation, Dec 7, 2012
Slide 1: Expansion of “On Pump” Concept to Cath Lab, EP lab
Expansion of “On Pump” Concept to Cath Lab, EP lab Evolution of Nonroller-Type CPB Pumps Surgical Cardiopulmonary Bypass (centrifugal) Percutaneous Cardiac Support (centrifugal) Percutaneous Cardiac Support (micro-axial) Percutaneous Cardiopulmonary Support (CPS) (centrifugal) 1960s 1980s Surgery su
Slide 2: FDA Clearance for Impella 2.5 (K063723)
FDA Clearance for Impella ® 2.5 (K063723 ) Supporting Clinical Data • Total of 129 patients • 100% from patients provided partial circulatory support ( < 6 hrs) during high risk PCI procedures (n=20 from FDA Safety Study , n=109 from EU registry) • 510(k) Summary for K063723: “Abiomed provided a det
Slide 3: Since its 510(k) clearance in 2008, >15,000 implants performed
Since its 510(k) clearance in 2008, > 15,000 implants have been performed, ~12,000 in the U.S. Impella ® Device
Slide 4: Sufficient Evidence on Impella to Identify Risks and Benefits
Sufficient Evidence on Impella ® to Identify Risks and Benefits 193 peer-reviewed publications since 1994 124 publications Meet Definition of “Valid Scientific Evidence” 57 pertain to use 6 hours CFR Section 860.7(c)(2): “Valid Scientific Evidence” – Well-controlled investigations – Partially contro
Slide 5: Largest Studies Supporting Reasonable Assurance
Largest Studies Supporting Reasonable N = 564 patients, 245 in FDA-approved protocol EU Registry US Registry IDE Safety Study IDE Randomized Study Study name Europella USpella PROTECT I PROTECT II Period 2004 - 2007 2009 - 2010 2006 -2007 2007- 2010 Tot. Patients HR PCI , N=144 HR PCI , N=175 HR PCI
Slide 6: FDA 515i Panel Classification Determination for Non-roller Type CPB Pumps: Clinical Evidence
10 FDA 515i Panel Classification Determination for Non-roller Type CPB Pumps Clinical Evidence December 6, 2012 Jeffrey J. Popma, MD Director, Interventional Cardiology, BIDMC Professor of Medicine, Harvard Medical School Disclosures: Research Grant, Advisory Board (1), Travel FDA 515i Panel Classif
Slide 7: Clinical Summary: Objectives-I
• FDA Executive Summary identified 5 studies using the Impella 2.5 device, comprising 231 patients undergoing HR-PCI. We would request that the Panel also consider additional analyses published after the 2011 ACC/AHA/SCAI guidelines not included in the FDA Summary. 11 • O’Neill et al The PROTECT II
Slide 8: Clinical Summary: Objectives-II
12 • FDA Executive Summary provides a preliminary overview of the primary endpoint of the PROTECT-II study as described by the DSMB. We would request that the Advisory Panel also consider: - PROTECT-II Pre-defined analysis population (PP) - PROTECT-II: Four pre-defined subgroup analyses - Other Regi
Slide 9: Slide 9
Slide 10: Slide 10
Slide 11: Impella 2.5 Clinical Evidence Base (N=799)
PROTECT I 1 Safety Feasibility Yes 20 JACC Interv. 2009 PROTECT II 2 Randomized Yes 452 (225) Circulation 2012 Cardio ByPass 3 Randomized No 199 (105) EJCTS 2002 Euro Registry 4 Multicenter Open Yes 144 JACC 2009 U.S. Registry 5 Multicenter Open No 175 CCI 2012 * Does not include control arm patient
Slide 12: Improved Hemodynamics with Impella 2.5
14 - Preserved cardiac power output with Impella v. IABP -4.2±24 v. -14.2±27 with IABP (P=0.001) • In cardiogenic shock - Improvement in cardiac index (ISAR-SHOCK) 0.49±0.46 L/min/M v. 0.11±0.31 L/min/M with IABP (P < 0.02) - Increase in mean arterial pressure (USPella) 83±17 mmHg v. 59±15 with cont
Slide 13: Inoperable High-Risk PCI: Hemodynamic Stability with Impella 2.5
15 Pre-PCI During PCI Left Main – Sole Remaining Vessel LVEF < 35% Inoperable High-Risk PCI: Hemodynamic Stability with Impella 2.5 Left Main – Sole Remaining Vessel LVEF < 35%
Slide 14: Inoperable High-Risk PCI: Hemodynamic Stability with Impella 2.5
16 60 80 Inoperable High-Risk PCI: Hemodynamic Stability with Impella 2.5
Slide 15: Slide 15
Slide 16: Slide 16
Slide 17: Safety: Risks For Temp Ventricular Support
17 Adapted from FDA Executive Summary: References in Appendix Potential Risks (use < 6 hrs) Reasonable Assurance to Support Safety Alteration in Blood Composition Large prospective RCT (N=199 patients) showed favorable results of Impella compared to CPB in OPCABG with respect to blood interaction 3
Slide 18: Safety: Risks For Temp Ventricular Support
References in Appendix Potential Risk (use < 6 hrs) Reasonable Assurance to Support Safety Adverse Tissue Reaction Two Large prospective RCT showed no evidence of adverse tissue 3 or blood 5 reaction compared to IABP 3 or CPB 5 respectively Infection 3.2% 1,2,4,5 Structural / Tissue Damage 0% in 3 F
Slide 19: CABG is Preferred in Patients with Complex Anatomy
19 CABG is Preferred in Patients with Complex Anatomy and Less Than High Surgical Risk
Slide 20: PROTECT II Trial Design
IMPELLA 2.5 + PCI IABP + PCI 1:1 R Patients Requiring Prophylactic Hemodynamic Support During Non-Emergent High Risk PCI on Unprotected LM/Last Patent Conduit and LVEF 35% OR 3 Vessel Disease and LVEF 30% 20 < < *Major Adverse Events (MAE) : Death, MI (>3xULN CK - MB or Troponin) , Stroke/TIA, Repea
Slide 21: Risk Assessment: SYNTAX vs PROTECT-II
21 1 2 SYNTAX (n=903) PROTECT II (n=448) Age (Mean±SD) 65±10 67±11 Diabetes (%) 26 52 Prior MI (%) 32 68 CHF (%) 4 87 Prior PCI (%) 0 39 Prior CABG (%) 0 33 LVEF 30% (%) 1.3 92 Not Surgical Candidate (%) 0 64 Euroscore (Mean±SD) 4±3 18±18 1 PCI arm in SYNTAX trial, Serruys et al. N Engl J Med. 2009;
Slide 22: PROTECT II Enrollment & Milestones
22 Initial Goal: 654 pts + 125 Patients 11/27/2007 PROTECT II 1 st st Patient 6/2/2008 510(k) Clearance 2/26/2010 50% Enrollment Achieved (N=327) 12/6/2010 69% Enrollment (N=452) 12/6/2010 Trial Halted for Futility Determination* *PROTECT II protocol Stopping rule for futility = power at interim ana
Slide 23: PROTECT II: ITT MAE (N=448)
IABP IMPELLA MAE= Major Adverse Event Rate. N=225 N=223 N=224 N=219 Log rank test, p=0.147 IABP 40.1% 49.3% 35.1% 40.6% 30 day MAE 90 day MAE 23 PROTECT II: ITT MAE (N=448) PROTECT II: ITT MAE (N=448) IABP IMPELLA MAE= Major Adverse Event Rate. p=0.277 p=0.277 N=225 N=223 p=0.066 p=0.066 N=224 N=219
Slide 24: CEC Adjudicated Adverse Events Directly Related to the Device in PROTECT II
Adverse Events Directly Attributed to the Device (90 days) Impella (N=225) IABP (N=223) Death 0 0 Stroke/TIA 0 0 Myocardial Infarction 0 0 Repeat Revascularization 0 0 Need for Cardiac ,Thorac. or Vasc. Operation 0 1 Acute Renal Dysfunction 0 0 CPR or VT req. Cardioversion 0 0 Increase in Aortic Ins
Slide 25: PROTECT-II: Additional Analyses in SAP
25 • Pre-Specified Population Analyses: Per Protocol • Predefined Secondary Analysis: - Learning Curve - Operator-Technique (Rotational Atherectomy) - Anatomic Indications (Left Main v. 3 V CAD) - Extreme Surgical Co-Morbidity (STS PROM) 25 PROTECT-II: Additional Analyses in SAP PROTECT-II: Addition
Slide 26: (0%) e764 UEAR esueApy JofeW SO 9
8 #2 e 8 8 a (0%) e764 UEAR esueApy JofeW 30 40 SO 60 70 80 9 20 Time post index procedure (days) 10 0
Slide 27: Time post index procedure (days)
20 30 40 50 60 70 80 90 Time post index procedure (days) 10 8 8 e 8 8 a & (0%) e724 WUEAR esuoApy sofeW ull
Slide 28: PROTECT II: Per Protocol MAE (N=427)
26 N=216 N=211 N=215 N=210 IABP IMPELLA 42.2% 51.0% 34.3% 40.0% 30 day MAE 90 day MAE Log rank test, p=0.048 IABP PROTECT II: Per Protocol MAE (N=427) PROTECT II: Per Protocol MAE (N=427) p=0.092 p=0.092 N=216 N=211 p=0.023 p=0.023 N=215 N=210 IABP IMPELLA Log rank test, p=0.048 IABP IMPELLA IMPELLA
Slide 29: Learning Curve: 1st Patient Excluded
90 day MAE Relative Risk [95% CI] Relative Risk [95% CI] Group p-value 1.02 [0.70, 1.48] 0.936 0.76 [0.59, 0.97] 0.92 [0.62, 1.38] 0.697 0.74 [0.58, 0.95] 1 Impella/IABP Patient @ each site (n=119) After 1 Impella/IABP Pt @ each site (n=324) 1 Impella/IABP Pt @ each site (n=116) After 1 Impella/IABP
Slide 30: Rotational Atherectomy: Sub-group
90 day MAE Relative Risk [95% CI] Relative Risk [95% CI] Group p-value 0.75 [0.59, 0.95] 1.19 [0.75, 1.91] 0.444 0.70 [0.55, 0.89] 1.19 [0.75, 1.91] 0.444 Atherectomy (n=52) No Atherectomy (n=391) Atherectomy (n=52) No Atherectomy (n=373) 28 0.014 0.003 Rotational Atherectomy: Sub-group Rotational A
Slide 31: Anatomy Sub-group: Left Main vs 3VD
90 day MAE Relative Risk [95% CI] Relative Risk [95% CI] Group p-value 0.88 [0.59, 1.33] 0.552 0.81 [0.63, 1.03] 0.077 0.82 [0.53, 1.25] 0.351 0.78 [0.61, 0.99] Left Main / Last Conduit (n=106) Left Main/ Last conduit (n=101) 3VD (n=324) 3VD (n=337) 29 0.039 Anatomy Sub-group: Left Main vs 3VD Anato
Slide 32: Excessive Surgical Co-Morbidity
90 day MAE Relative Risk [95% CI] Relative Risk [95% CI] Group p-value 1.08 [0.71, 1.63] 0.733 0.77 [0.61, 0.98] 1.14 [0.75, 1.71] 0.540 0.71 [0.56, 0.91] STS 10 (n=73) STS < 10 (n=370) STS 10 (n=71) STS < 10 (n=354) 30 0.030 0.006 Excessive Surgical Co-Morbidity Excessive Surgical Co-Morbidity Inte
Slide 33: Ongoing US Impella Registry
• Observational open registry for Impella in North America • Sites invited to participate on June 10, 2009 • 949 patients enrolled to-date at 41 centers • Includes all consecutive, unselected patients at each site • Data obtained after IRB approval • Data monitoring against source documentation • In
Slide 34: Consistent Results in High-Risk PCI Impella Registries
32 US Registry (175) EU Registry (N=144) 30 day Outcomes (%) Death related to the device All causes of Death Myocardial Infarction Stroke Revascularization Bleeding req. surgery Site bleeding req. transfusion Vascular complications Valve damage Hemolysis 0 4.0 1.1 0.6 0.6 1.7 3.4 4.0 0 0 0 5.5 0 0.7
Slide 35: Summary
33 • Safety concerns mitigated with review of all available clinical evidence associated with the use of the Impella 2.5 • Substantial improvements in hemodynamics have been demonstrated with Impella 2.5 v. IABP • Examination of the totality of the clinical evidence associated with the use of the Im
Slide 36: Conclusion
34 • Comprehensive review of the totality of clinical evidence associated with the use of the Impella 2.5 device for its labeled “< 6 hour” indication supports the safety and efficacy of this device, particularly in patients undergoing high-risk PCI • Ongoing surveillance with a comprehensive Nation
Slide 37: References
35 1. Dixon SR, Henriques JP, Mauri L, Sjauw K, Civitello A, Kar B, Loyalka P, Resnic FS, Teirstein P, Makkar R, Palacios IF, Collins M, Moses J, Benali K, O'Neill WW. A prospective feasibility trial investigating the use of the Impella 2.5 system in patients undergoing high-risk percutaneous corona
Slide 38: Special Controls Have Been Identified and Implemented to Mitigate Known Risks
Special Controls Have Been Identified and Implemented to Mitigate Known Risks 1. Extensive testing submitted for 510(k): Non-clinical Performance/Bench testing (41 tests on average per application) Clinical data (Impella 2.5: 129 patients) Testing includes evaluations of structural/tissue damage to
Slide 39: General and Special Controls are In Place to Mitigate Potential Risks
General and Special Controls are In Place to Mitigate Potential Risks to Public Health Potential Risk (use < 6 hrs) Implemented Controls Alteration in blood composition Performance/Bench Testing, Labeling, Registry Inadequate tissue perfusion Performance/Bench Testing, Labeling, Registry Embolism Pe
Slide 40: General and Special Controls are In Place to Mitigate Potential Risks
General and Special Controls are In Place to Mitigate Potential Risks to Public Health Potential Risk (use < 6 hrs) Implemented Controls Structural/tissue damage to heart Performance/Bench Testing, Labeling, Training, Registry Local heat generation Performance/Bench Testing, Registry Flow dynamics P
Slide 41: Recommendation to Expand US Impella Registry
• Abiomed Recommendation: Establish an inclusive Prospective National Registry of Percutaneous Circulatory Support • Leveraging current infrastructure of the Impella Registry • On-going registry, in cooperation with FDA and the appropriate professional society, would enhance the current risk mitigat
Slide 42: 510(k) Number 063723 Indications for Use
510(k) Number (if known): 063723 Device Name: IMPELLA RECOVER® LP 2.5 Percutaneous Cardiac Support System Indications for Use: The iMPELLA RECOVER® LP 2.5 Percutaneous Cardiac Support System is intended for partial circulatory support using an extracorporeal bypass control unit, for periods up to 6
Slide 43: Conclusion
For temporary ventricular support up to 6 hours, including support provided during HRPCI, Impella meets the requirements for a class II designation Conclusion Further, we recommend the establishment of a prospective national registry of percutaneous circulatory support as an added special control fo
Slide 44: Thank you
Thank you
Slide 45: Impella MDR Rate Compared to IAB
(thru 11/15/12) Impella ® MDR Rate Compared to IAB * * Assumes 75,000 IABs used each year 0.01% 0.07% 0.16% 0.03% 0.07% 0.73% Death Injury Malfunction Impella IAB 1.13% 0.32% 0.44% 0.26% 0.23% 0.44% 0.88% 1.36% 0.78% 0.42% 2008 2009 2010 2011 2012 Impella IAB
Slide 46: Procedural Characteristics
Procedural Characteristics IABP (N=211) Impella (N=216) p-value Use of Heparin 82.4% 93.5% IIb/IIIa Inhibitors 26.5% 13.4% Total Contrast Media (cc) 241±115 267±141 Rotational Atherectomy (RA) 9.0% 14.2% Median # of RA Passes/lesion (IQ range) 1 (1-2) 3 (2-5) Median # of RA passes/pt (IQ range) 2.0
Slide 47: Hemodynamic Support Effectiveness
CPO= Cardiac Power Output = Cardiac Output x Mean Arterial Pressure x 0.0022 (Fincke R, Hochman J et al JACC 2004; 44:340-348) Cardiac Power Output Maximal Decrease in CPO on device Support from Baseline (in x0.01 Watts) IABP Impella N=138 N=141 - 4.2 ± 24 - 14.2 ± 27 CPO data available only for 279
Slide 48: CoreLab Analysis Shows No Evidence of Damage to Cardiac or Valve Structures
Aortic/Mitral valve injury Valve prolapse Chordal rupture Papillary muscle rupture Aortic aneurysm Structural damage to heart chambers or septum 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% Structure PROTECT I (N=20) 1 PROTECT II (N=225) 2 1 Dixon et al. JACC Interv. 2009; 2 O’Neill et al Circulation 2012 Co
Slide 49: Over 330 Cases with Imaging Showing No Valve Trauma
49 O’Neill et al 2012 Maini et al 2012 Chandola et al 2012 Dixon et al. 2009 Henriques and al. 2006 Valgimigli and al. 2005 Vlasselaers and al. 2005 Meyns and al. 2003 Siengenthaler and al. 2005 Cantena and al. 2005 Catena and al. 2004 Colombo and al. 2003 Strecker and al. 2004 Jurmann and al. 2004
Slide 50: Results of a Randomized Study Supports Blood Compatibility of Impella
50 Leucocytes (10x9/l) Granulocytes (%) Eosinophilic leucocytes (%) Basophilic leucytes (%) Monocytes (%) Lymphocytes (%) Platelets (10x9/l) Antithrombin III (%) D-Dimers (ug/dl) Granulocyte elastase (ug/l) Complement C3 (g/l) IMPELLA (n=105) 12.3 ± 4.4 78 ± 8.1 1.48 ± 0.98 0.65 ± 0.41 5.31 ± 2.56 1
Slide 51: Study Device Learning Curve Effect
51 MAE= Major Adverse Event Rate N=91 N=85 N=64 N=68 N=69 N=66 90day MAE Outcome IABP IMPELLA 2008 2009 2010 MAE= Major Adverse Event Rate N=91 N=85 N=64 N=68 N=69 N=66 Study Device Learning Curve Effect Study Device Learning Curve Effect 90day MAE Outcome Intent-to-Treat Intent-to-Treat IABP IMPELL
Slide 52: PROTECT II MAE Outcome
52 Pre-specified High Risk PCI Without Atherectomy Group MAE= Major Adverse Event Rate 39.6% 48.7% 30.6% 38.5% 30 day MAE 90 day MAE N=192 N=202 N=193 N=203 Log rank test, p=0.03 Intent-to-Treat (N=396) IABP IMPELLA PROTECT II MAE Outcome PROTECT II MAE Outcome Pre-specified High Risk PCI Without At
Slide 53: Confounder: Use of Atherectomy
90 day MAE Relative Risk [95% CI] Relative Risk [95% CI] Group p-value Interaction p-value 0.79 [0.64, 0.97] 0.70 [0.55, 0.89] 1.25 [0.75, 1.91] 0.444 Pre-Specified Sub-group Analysis With Atherectomy (n=52, 12%) Without Atherectomy (n=373, 88%) MAE = Major Adverse Event ; Per Protocol (PP)= Patient
Slide 54: Comparative Cost-Effectiveness Studies
54 1. Earnshaw, et al. Arch. of Intern Med., 2011. 2. Feldman, et al. JACC, 2005. COMPANION 3. Choudhry, et al. JACC, 2011. JUNIPER 4. Chen, et al. ISPOR, 2009.CHARISMA <$100,000 Threshold 9. Winkelmayer, et al. Medical Decision Making, 2002. 10. Moore, et al. BMC Health Services Research 2009 11. S